Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

Fig. 4

Percentage of patients who were persistent on index therapy for 12 or 24 months over time. The percentage of patients who persisted on index therapy for 12 and 24 months was determined for the treatment cohorts over the time periods of 2004–2007, 2008–2011, and 2012–2015. Patient cohorts were defined by the first treatment initiation after enrollment into Corrona and were mutually exclusive. Superscript lowercase letter “a” indicates non-TNFi and tsDMARD. csDMARD, conventional synthetic disease-modifying antirheumatic drug; TNFi, tumor necrosis factor inhibitor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us